BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1714686)

  • 1. The effect of weight correction on risk calculations for Down's syndrome screening.
    Reynolds TM; Penney MD; Hughes H; John R
    Ann Clin Biochem; 1991 May; 28 ( Pt 3)():245-9. PubMed ID: 1714686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.
    Extermann P; Bischof P; Marguerat P; Mermillod B
    Hum Reprod; 1998 Jan; 13(1):220-3. PubMed ID: 9512261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight.
    Wald NJ; Cuckle HS; Densem JW; Kennard A; Smith D
    Br J Obstet Gynaecol; 1992 Feb; 99(2):144-9. PubMed ID: 1372820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Stone RB
    Br J Obstet Gynaecol; 1992 Jan; 99(1):51-3. PubMed ID: 1372176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal serum screening for Down's syndrome in early pregnancy.
    Wald NJ; Cuckle HS; Densem JW; Nanchahal K; Royston P; Chard T; Haddow JE; Knight GJ; Palomaki GE; Canick JA
    BMJ; 1988 Oct; 297(6653):883-7. PubMed ID: 2460174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal serum markers for Down's syndrome pregnancies.
    Chew S; Anandakumar C; Ratnam SS
    Singapore Med J; 1995 Aug; 36(4):417-23. PubMed ID: 8919160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
    Wald NJ; Kennard A; Densem JW; Cuckle HS; Chard T; Butler L
    BMJ; 1992 Aug; 305(6850):391-4. PubMed ID: 1382768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of maternal serum alpha-fetoprotein, human chorionic gonadotrophin and oestriol in the antenatal screening of Down's syndrome.
    Chang TC; Cheng HH
    Med J Malaysia; 1994 Dec; 49(4):351-4. PubMed ID: 7545778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight correction of MoM values: which method?
    Reynolds TM; Vranken G; Van Nueten J
    J Clin Pathol; 2006 Jul; 59(7):753-8. PubMed ID: 16603647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appraisal of a new scheme for prenatal screening for Down's syndrome.
    Sheldon TA; Simpson J
    BMJ; 1991 May; 302(6785):1133-6. PubMed ID: 1710520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of maternal serum for fetal Down's syndrome in the first trimester.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
    N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Nanchahal K; Canick JA; Haddow JE; Knight GJ; Palomaki GE
    Br J Obstet Gynaecol; 1988 Apr; 95(4):334-41. PubMed ID: 2454652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
    Piggott M; Wilkinson P; Bennett J
    J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
    Wald NJ; Watt HC
    Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Noninvasive serum test for prenatal detection of Down syndrome, other chromosome abnormalities and open neural tube defects--a prospective study].
    Zwahr C; Voss P; Kistner G
    Geburtshilfe Frauenheilkd; 1994 Jun; 54(6):355-61. PubMed ID: 7522195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.